Government needs to act to address ‘sugar rush' of corporation taxes, says Ictu
Irish Congress of Trade Unions
(Ictu) has said.
Speaking ahead of the National Economic Dialogue, an annual event taking place at Dublin Castle on Monday, Ictu general secretary
Owen Reidy
said the Government needed to act in order to end the State's reliance on the 'sugar rush' currently provided by
corporation tax
.
While the economy was clearly doing well on the face of it, Mr Reidy said: 'We know that headline figures don't tell the full story of the Irish economy.
'We have an over-reliance on a handful of firms for corporation tax, significant wage inequality and major infrastructure deficits across housing, healthcare and transport.
READ MORE
'
Budget
2026 must mark a turning point by giving certainty and security to workers across Ireland. That means good jobs that pay well, a decent standard of living, as well as stronger public services. But it should also mean a shift in our economic model.'
Mr Reidy said Ictu would be publishing submissions in the coming weeks outlining how it feels the Government should address the issues involved and 'start serious planning for the longer term'.
Figures published in January indicated the amount of money paid in corporation tax to the State increased by 18 per cent last year to €28 billion. This excluded the €11 billion windfall arising from the
Apple tax
case.
In contrast, some €35 billion was generated in income
tax
last year with €21.8 billion coming via
VAT
receipts and €6.3 billion from excise duties. This means corporation taxes accounted for about a quarter of all Government revenue last year.
While the corporation tax take is expected to increase further this year, there have been repeated warnings about State finances being overly reliant on it.
Speaking ahead of Monday's conference, which will be attended by representative bodies from across the economy and addressed by the Taoiseach, Tánaiste and senior Ministers, Mr Reidy said: 'We'll be urging Government to create genuine economic certainty by investing in infrastructure and research, strengthening workplace democracy, reducing inequality and ending the fiscal gimmickry of the past.'
He said action was needed given the current economic uncertainty.
Meanwhile, Ictu has been arguing in recent months for a long list of changes to employment regulation as part of an action plan the Government is required to publish in relation to the European Union Directive on Adequate Minimum wages, which the unions hope will pave the way for far wider collective bargaining.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
6 hours ago
- Irish Times
Gareth Sheridan: Nutriband ‘will help a lot of people who are dealing with addiction and people who are dealing with pain'
Nutriband is a pharmaceutical company that was founded in Dublin in 2012 before relocating to Florida in 2016. Gareth Sheridan, who recently announced his intention to run for president and has stepped aside for three months as chief executive, is its founder. The company's lead product is Aversa, which it describes as 'abuse-deterrent transdermal technology', which incorporates aversive agents to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, specifically opioids. Its first application is its abuse-deterrent fentanyl transdermal patch, which it is developing to provide clinicians and patients with extended-release chronic pain relief. It is awaiting regulatory clearance for this product in the US. The company has operations in Florida, Georgia, and North Carolina, and recently began its expansion back to Dublin. READ MORE What lightbulb moment prompted you to start-up in business? It was originally a thesis idea. I had noticed a patch that my dad wears and began wondering what other types of medications could be delivered that way that had not been explored yet. The thesis became a business plan, and Nutriband was registered in 2012. Describe your business model and what makes your business unique. We structured the company in a unique way, using capital markets and a public listing approach. We listed on the OTC Markets in 2016 and started using stock to purchase companies and technologies in place of cash. This helped us to avoid raising expensive early capital and retain a major equity stake in the company today, even after an eventual qualification to list on the Nasdaq (in New York) in 2010. We also do not develop new drug applications. We take existing generic medications and use our technologies to improve upon those and relaunch them as a branded product again. What is your greatest business achievement to date? Growing the company to a level where we qualified to list on the Nasdaq Stock Exchange and getting to ring the opening bell. What was your back-to-the-wall moment and how did you overcome it? We almost got sued by the SEC (The US Securities and Exchange Commission) for an accidental erroneous disclosure in one of our filings while on the OTC markets. At first, we thought it could be explained. However, it grew to the point where they were doubling down. We hired an excellent attorney with SEC experience and eventually settled the issue in a cease-and-desist, no-admit, no-deny agreement. This led to our back-to-the-wall moment, where, while running on fumes financially, we received a rejection from Nasdaq in our first application. After a couple of days of self-pity, we got back to work, raised some working capital with existing shareholders, and grew the company's equity by $7.5 million (€6.4 million) over the course of the next year. We reapplied to list again successfully. What moment would you cite as a turning point for the company? Credibility provided by our Nasdaq listing and subsequent partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery), where Kindeva supplied their generic approved fentanyl patch for us to add our technology to. What were the best and the worst pieces of advice you received when starting out? The worst advice was that banks and institutions have your company's best interests at heart. I firmly believe that today, Wall Street is built on companies failing, not succeeding. Describe your growth funding path. We were reluctant to raise expensive capital early on and instead listed the company to use stock as an acquisition currency to grow. Our gamble on this paid off, and although we raised modest cash along the way, we were able to build Nutriband without any significant seed or angel rounds. We reached a market capitalisation of $120 million (its market value currently is about $75 million), and we have been able to maintain stable and steady control as a result of the minimal capital rounds. We turn down anywhere from $5 million to $15 million on a weekly basis from funds and institutions because we do not need it. We are not in the business of raising money, and having as little dilution as possible is a core focus for us as a company. How will your market look in three years and where would you like your business to be? For our first product, we are expected to reach annual revenues of $200 million. Our second product is independently estimated to have upwards of $135 million in yearly revenue. We are targeting the billion dollar club before the end of 2027. What are your annual revenues and profits? We are not yet profitable, as is typical with clinical development-stage companies. However, we also contract manufacture sports tapes and products for brands such as Reebok and KT Tape. Our target revenue from this source for the financial year to the end of January 2026 is $3 million * . This goes towards operational costs and reduces our clinical burn. Why have you decided to seek a nomination for the presidency? It's never been a more important or relevant time in our history for a young president, particularly with the average age just under 40. I would be hoping that having a younger president would help narrow the division we're seeing in the country at the moment and that we can work together to tackle the issues, particularly the housing crisis. The younger generation aren't feeling very enthusiastic that their voices are being heard. What impact will this move have on your business? The company is in very safe hands and the biggest asset at the company is the team. We've got a very definite plan and timeline between now and Christmas on what needs to be achieved. Whether I'm in there or not that timeline needs to be adhered to. The company is motoring along fine. Stepping aside is not something that I think will fundamentally affect the opportunity for the company. What happens if you win? There are mechanisms where I can put the shares into a trust. I would be very proud that it was a company that I started and be very keen to still follow the journey, just not as CEO. Nutriband as a whole is going to do a lot of will help a lot of people who are dealing with addiction and people who are dealing with pain. *An earlier version of this article stated a higher target figure for contract manufacturing, which has since been revised by the company.
Sunday World
6 hours ago
- Sunday World
Man who killed Irish soldier Seán Rooney believed to be on the run in Iran
The runaway killer fled Lebannon and is said to be hiding in Iran. The man who killed Private Sean Rooney is believed to be hiding out in Iran, according to sources. Hezbollah fighter Mohammed Ayyad has not been seen in over a year but Government and diplomat sources suspect he has fled Lebanon for Iran. The runaway killer was sentenced to death a few weeks ago on July 28 last by a military tribunal for the murder of the 23-year-old Dundalk soldier. But he wasn't in court for the conviction and the Lebanese authorities gave no indication where he was. Ayyad was initially released on bail over a year ago on medical grounds. But yesterday the Louth Sinn Fein TD Ruairi O'Murchu said it is unclear what his medical condition was. rooney News in 90 Seconds - August 16th He said: 'This guy seems to have vanished and nobody knows where he is." But Government insiders believe Ayyad has fled to Iran - the country which bankrolls the Hezbellah organisation in south Lebanon where Sean perished. One source said: 'We suspect he is in Iran and it is unlikely anyone will hand him over to face a death penalty. It is not a satisfactory situation but all we can do is keep the pressure on and see if we can get justice for Sean and his family." Ayyad was among a gang of men who opened fire on the UN peacekeepers convoy on December 14, 2022 in the village of Al-Aqbiya as they made their way to Beirut Airport. Sean lost his life while three other Irish soldiers, Private Shane Kearney, Corporal Joshua Phelan, and Private Nathan Byra were injured. The other Lebanese gunmen involved in the unprovoked attack got far lighter sentences. One got three months jail, another a one month jail sentence, another was fined the equivalent of appoximately €1800 and a fourth was acquitted. These are now being appealed by the Beirut government following pressure from Ireland and Sean's devastated family. The Minister for Defence Simon Harris and Sean's mother Natasha held a private meeting to discuss the case during the week. Mr Harris said: " The Government has repeatedly stressed the need for justice to be served in this case.. We have raised the issue with the UN, and the Lebanese authorities . This is a difficult time for his family and the 121th Infantry Battalion." The Lebanese authorities have not executed any prisoners in over 20 years so the Irish Government is pushing for the killer to be found to serve a life in prison instead. The Taoiseach Micheal Martin after the court verdict said: 'Sean was a soldier of great courage who put the safety of others before his own safety in the line of duty. He was brave and diligent. "Peacekeeping is the most noble cause of all and the role of the peacekeeper must at all times be honoured and respected." The Irish Coroner's Inquest into Sean Rooney's death has been postponed and no new date confirmed. Defence Minister Harris revealed in a reply to Deputy O'Murchu that the Coroner has received a response from the United Nations to her request that they should be an interested party at the Inquest and grant access to a number of UN reports. Details of the UN response have not been released publicly. Mr Harris also said that an independent review into the murder by Mr Michael Delaney SC is ongoing. This review is examining the internal tactics, techniques , processes, and procedures employed by the Defence Forces with a view to determining whether there are lessons to be learned for the circumstances surrounding Private Rooney's death. Mr Delaney nis expected to report with Mr Harris in the autumn.
Agriland
7 hours ago
- Agriland
Stakeholder group meets amid 'heightened uncertainty' around derogation
The Better Farming for Water Stakeholder Steering Group met in Teagasc Oak Park in Co. Carlow this week, amid "heightened uncertainty" around the nitrates derogation. The meeting discussed the emergent policy situation in relation to the "more intense linkage" between the Nitrates Directive and the Habitats Directive as Ireland engages with the European Commission to retain its derogation. According to Teagasc, the committee acknowledged the "heightened uncertainty of the current policy position for farm families", while "unanimously acknowledging their considerable commitment and actions in delivering improved water quality". "As further evidence, 3,895 farmer applications have been made to the €50 million Farming for Water EIP Fund, including a substantial number of applications by grain growers for the planting of catch crops to take up nitrogen over the winter period," Teagasc said. "The committee reaffirmed its belief that achievement of the objective of good, or high ecological status in our waterbodies is fundamental to retaining Ireland's derogation and compliance with the Habitats Directive and to maintaining the reputation for sustainability that Irish food enjoys. "It is clear that responsibility for this objective rests with 'all farmers' regardless of farm enterprise and not just 'derogation farmers'." The current challenge from the European Commission is for Ireland to "provide clarity and assurances on compliance" with the Habitats Directive in the granting of derogations as part of its application for continuance of the facility, Teagasc said. Jim Bergin, chair of the stakeholder steering group - which is comprised of representatives from Teagasc, government, farm organisations and more - said members "unanimously agree that a whole of government and whole of sector aligned approach is the best avenue towards optimising Ireland's position". He said it "should be considered not only in relation to the scientific approach to assessment, but also the future economic and social impacts of the plan on farm families". 'Even though there is much work to be done in order to achieve clarity on the current position, the committee fully acknowledges the importance of communicating with farm families at appropriate junctures in order to support them through this concerning period, and to reflect their progress towards improved water quality," Bergin said. Bergin said he is "really encouraged both by the recent data from the Environmental Protection Agency showing improvement in the nutrient content of our waterways, and more importantly, the collective, combined effort by all sections of the agriculture sector to address water quality.' At the meeting also, Noel Meehan, head of Teagasc's water quality knowledge transfer department, provided an update on the establishment by Teagasc of 'catchment implementation groups' focused on eight of the main river catchments and their sub-catchments. The groups will include representatives from relevant farm organisations, processors of meat, dairy and grain in the catchments, regulatory authorities, catchment-based community groups and advisory groups.
